Cocrystal Pharma (COCP)
(Delayed Data from NSDQ)
$1.76 USD
+0.01 (0.57%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.74 -0.02 (-1.14%) 5:18 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.76 USD
+0.01 (0.57%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.74 -0.02 (-1.14%) 5:18 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19
by Zacks Equity Research
Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.
Cocrystal Pharma (COCP) Jumps: Stock Rises 7.3%
by Zacks Equity Research
Cocrystal Pharma (COCP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Cocrystal Pharma (COCP) Completes Research Obligations With Merck
by Zacks Equity Research
Cocrystal (COCP) completes all research obligations under the Merck exclusive worldwide license and collaboration agreement.
Company News for Mar 10, 2020
by Zacks Equity Research
Companies In The News Are: COCP, CGEN, AAPL, NINE
Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges
by Zacks Equity Research
With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.